Biogen Idec BIIB and Stromedix, Inc. today announced that they have
entered into a definitive agreement under which Biogen Idec will acquire
Stromedix Inc., a privately held biotechnology company focused on innovative
therapies for fibrosis and organ failure. Under the terms of the agreement,
Biogen Idec will make an upfront cash payment of $75 million and additional
contingent value payments of up to $487.5 million based on the achievement of
certain development and approval milestones across multiple indications.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in